Janssen Marks First Approval Worldwide for TECVAYLI?(teclist

Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1 The

Related Keywords

United States , American , Jenni Mildon , Williamn Hait , Maria Victoria Mateos , Peter Lebowitz , Edmond Chan , None Of The Janssen Pharmaceutical Companies , American Society Of Clinical Oncology , European Commission , Global Public Health , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , University Hospital Of Salamanca , Companies Of Johnson , European Medicines Agency , European Medicines Agency Ema Priority , Committee For Medicinal Products Human Use , Johnson , American Cancer Society , Consultant Physician , University Hospital , Senior Director , Area Lead Haematology , Confidence Interval , New England Journal , Global Therapeutic Area Head , Executive Vice President , Chief External Innovation , Medical Safety , Global Public Health Officer , Medicinal Products , Human Use , Pharmaceutical Companies , Metabolism Retina , Infectious Diseases Vaccines , Janssen Cilag Limited , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Med Sci , European Medicines , Escalation Study , Participants With Relapsed , Refractory Multiple Myeloma , Refractory Multiple , Subcutaneous Daratumumab Regimens , Participants With Multiple , Combination With Daratumumab Subcutaneously , Versus Daratumumab , Today Population Factsheets , Janssen , Parks , First , Approval , Orldwide , Tecvayli , Teclistamab , Authorisation , Glass , Bispecific , Ntibody , Treatment , Patients , Multiple , Myeloma ,